Page 60 - அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evinacumab shows promise in severe hypertriglyceridemia trial

Evinacumab shows promise in severe hypertriglyceridemia trial SHARES The investigational antibody evinacumab was able to lower triglycerides by up to 82 percent in severe hypertriglyceridemia patients with acute pancreatitis. In a global Phase II study, the investigational monoclonal antibody (mAb) evinacumab was able to reduce triglycerides in patients with severe hypertriglyceridemia and a history of hospitalisations for acute pancreatitis. Dependent on genotype, the fully human mAb produced sustained reductions in triglyceride levels of up to 82 percent, while also lowering the risk of recurrent acute pancreatitis. The results of the study were presented as a late-breaking clinical trial at the American College of Cardiology (ACC) Annual Scientific Session on 16 May 2021.

Robert rosensonIcahn school of medicine at mount sinaiAmerican college of cardiologyDrug administrationLipids for the mount sinai health systemAmerican collegeAnnual scientific sessionIcahn schoolMount sinaiMount sinai healthஇக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினைஅமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்அமெரிக்கன் கல்லூரிஆண்டு அறிவியல் அமர்வுஇக்ஹ்ன் பள்ளிஏற்ற சினை

Tailored, earlier cardiac rehab program shows physical, emotional benefits for heart failure patients

An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty,.

Winston salemNorth carolinaUnited statesDuke universityDalanew kitzmanEvan hadleyRichardj hodesWake forest school of medicineAmerican college of cardiologyDivision of geriatricsNational institute on agingNational instituteNew england journalAmerican collegeAnnual scientificWake forest school

Clopidogrel superior to aspirin for long-term post-stent maintenance

E-Mail Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long-term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy (DAPT) following the insertion of a coronary stent. After two years of follow-up, chronic maintenance therapy with clopidogrel resulted in a 30% reduction in deaths, heart attacks, strokes or major bleeding events, according to research presented at the American College of Cardiology s 70th Annual Scientific Session. These data confirm our working hypothesis that long-term maintenance antiplatelet monotherapy with clopidogrel produces better outcomes than aspirin in patients who are adverse event-free at one year after coronary stenting, said Hyo-Soo Kim, MD, PhD, professor of internal medicine at Seoul National University Hospital in South Korea and lead author of the study.

Soult ukpyolsiSouth koreaHyo soo kimNicole napoliYann nguyenAntiplatelet monotherapySeoul national university hospitalAmerican college of cardiologyKorean ministry of healthAmerican collegeAnnual scientificSouth korean ministryHost exam randomized controlled trialதெற்கு கொரியாஹயோ சூ கிம்நிக்கோல் ந்யாபலீ

Astrazeneca PLC (NYSE:AZN), (AZNCF) - AstraZeneca s Farxiga Flunks Late-Stage COVID-19 Study

Astrazeneca PLC (NYSE:AZN), (AZNCF) - AstraZeneca s Farxiga Flunks Late-Stage COVID-19 Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

American college of cardiologyAmerican collegeஅமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்அமெரிக்கன் கல்லூரி

De-escalation of dual antiplatelet therapy appears safe and effective

Among patients who had a cardiac stent inserted after a heart attack, switching to less-potent dual antiplatelet therapy (DAPT) after 30 days was safer and more effective in preventing adverse events a year later than continuing on a high-potency DAPT regimen, according to data presented at the American College of Cardiology s 70th Annual Scientific Session.

Soult ukpyolsiSouth koreaChong kun dang pharmNicole napoliYann nguyenKiyuk changDivision of internal medicineAmerican college of cardiologyCatholic university of koreaAmerican collegeAnnual scientificInternal medicineCatholic universityEast asiaEast asianChong kun dang